Streetbeat News

CMMB

Chemomab Therapeutics Ltd.

https://www.chemomab.com

Industry

Biotechnology

Chemomab Therapeutics Ltd., a clinical-stage biotech company, discovers and develops therapeutics for the treatment of inflammation and fibrosis. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was incorporated in 2011 and is based in Tel Aviv, Israel.

Open

1.69

Mkt cap

25M

Volume

259K

High

1.79

P/E Ratio

-1.58

52-wk high

2.55

Low

1.59

Div yield

N/A

52-wk low

0.42

Chemomab presented two scientific posters at EASL 2024, supporting the clinical rationale for its Primary Sclerosing Cholangitis (PSC) program.

Portfolio Pulse from Benzinga Newsdesk

June 06, 2024 | 11:22 am

Maxim Group analyst Michael Okunewitch initiates coverage on Chemomab Therapeutics (NASDAQ:CMMB) with a Buy rating and a price target of $4.

Portfolio Pulse from Benzinga Newsdesk

May 13, 2024 | 4:32 pm

Chemomab Therapeutics' stock is trading higher following the announcement of improved year-over-year Q1 GAAP EPS results.

Portfolio Pulse from Benzinga Newsdesk

May 09, 2024 | 4:47 pm

Chemomab Therapeutics (NASDAQ:CMMB) reported a significant reduction in its quarterly losses to $(0.28) per share in Q1 2024, improving from a loss of $(0.80) per share in the same quarter the previous year, marking a 65% increase in performance.

Portfolio Pulse from Benzinga Newsdesk

May 09, 2024 | 11:10 am

Chemomab Therapeutics has received a 180-day extension from Nasdaq to meet the minimum bid price requirement for continued listing. This extension provides the company additional time to comply with Nasdaq's listing rules by increasing its stock price to the required minimum bid level.

Portfolio Pulse from Benzinga Newsdesk

May 08, 2024 | 11:15 am

Health care stocks experienced significant movements in Monday's intraday session, with NRX Pharmaceuticals, TC BioPharm, Outset Medical, Nanoviricides, Chemomab Therapeutics, and Titan Pharma among the gainers. Conversely, Lyra Therapeutics, GlycoMimetics, EyePoint Pharmaceuticals, Acutus Medical, Integra Lifesciences, and Helius Medical Technologies were notable losers. The movements were attributed to various factors, including earnings reports for some companies.

Portfolio Pulse from Benzinga Insights

May 06, 2024 | 4:31 pm

Chemomab Therapeutics' stock price increased following an upgrade by Oppenheimer from Perform to Outperform, with a new price target set at $6.

Portfolio Pulse from Benzinga Newsdesk

May 06, 2024 | 2:20 pm

Oppenheimer analyst Jeff Jones upgrades Chemomab Therapeutics (CMMB) from Perform to Outperform with a $6 price target.

Portfolio Pulse from Benzinga Newsdesk

May 06, 2024 | 11:52 am

Chemomab Therapeutics' stock price increased following the announcement of a new study that supports the clinical relevance of its CCL24 target in systemic sclerosis, linking it to disease severity and mortality.

Portfolio Pulse from Benzinga Newsdesk

April 18, 2024 | 4:59 pm

Chemomab announced a new peer-reviewed publication that supports the clinical association of its CCL24 target with disease severity and mortality in Systemic Sclerosis (SSc). A longitudinal study of over 200 real-world patients further validates CCL24 as a novel target for SSc, indicating its association with disease severity across fibrotic and vascular manifestations of the condition.

Portfolio Pulse from Benzinga Newsdesk

April 18, 2024 | 11:11 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.